S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
HRTX · Heron Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Heron Therapeutics Inc (HRTX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.34
-0.02
(-5.71%)
● At close: October 21 at 4:00:00 PM EDT
$0.33
-0.01
(-2.48%)
Overnight:
8:33:49 PM EDT
DAY'S RANGE
$0.34
$0.33
$0.35
52-WEEK RANGE
$0.34
$0.26
$1.58
What's happening
- HRTX is down 5.71% today, trading at $0.34. — Live quote
- Volume today (12,379) is well below its 3-month average of 2,823,610. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.03 actual vs. $0.01 estimated (-394.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 4
Sell 1
Strong sell 2
Aggregate ratings for 2026-09-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
HRTX
-72.15%
vs S&P 500
-85.01%
1-YEAR RETURN
HRTX
-72.58%
vs S&P 500
-88.79%
6-MONTH RETURN
HRTX
-57.41%
3-MONTH RETURN
HRTX
-17.54%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.03
Est. $0.01
MISS -394.1%
2026-04-26 (Q1 2026)
$-0.04
Est. $-0.02
MISS -161.4%
2026-01-26 (Q4 2025)
$-0.02
Est. $-0.02
BEAT +2.0%
2025-10-26 (Q3 2025)
$-0.04
Est. $-0.02
MISS -161.4%
Valuation Measures & Ratios
Enterprise Value4$190.7M
Forward P/E5—
PEG Ratio6-0.00
Price / Sales (TTM1)0.45
Price / Book711.69
EV4 / Revenue1.26
EV4 / EBITDA80.92
Profit Margin-22.52%
Operating Margin-14.69%
Return on Equity (ROE8)-300.90%
Return on Assets (ROA9)-13.57%
Avg Volume (3M)2,823,610
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $78.3M | $161.6M | $220.4M | $245.8M | $578.4M |
| P/E | -2.34 | -6.37 | -9.98 | -17.78 | -39.59 |
| Price/Book | 11.33 | 17.68 | 14.81 | -9.02 | -20.33 |
| EV/EBITDA | -5.57 | -26.90 | -37.93 | — | — |
| ROE | -484.60% | -277.47% | -148.40% | 50.73% | 51.34% |
| ROA | -13.27% | -10.30% | -8.87% | -5.96% | -6.20% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short46,021,379
Change from Prior Settlement+6.09%
% of Float—
Days to Cover (Short Ratio)17.30
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 1.2% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -22.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -72.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on HRTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | $26.1M | $24.1M | $26.3M | $27.3M | $30.4M | $23.4M | $25.5M | $26.2M |
| Operating income | -$2.0M | -$4.8M | -$4.1M | -$1.6M | $3.2M | -$4.5M | -$6.4M | -$4.8M |
| Net income | -$5.5M | -$8.1M | -$17.5M | -$2.4M | $2.6M | -$4.8M | -$9.2M | -$3.2M |
| EPS (diluted) | $-0.03 | $-0.04 | $-0.10 | $-0.02 | $0.01 | $-0.03 | $-0.06 | $-0.02 |
| EPS (basic) | $-0.03 | $-0.04 | $-0.10 | $-0.02 | $0.02 | $-0.03 | $-0.06 | $-0.02 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $252.3M | $246.2M | $255.9M | $248.9M | $232.1M | $235.8M | $233.1M | $220.8M |
| Total liabilities | $245.4M | $237.1M | $241.5M | $234.1M | $259.3M | $264.2M | $266.8M | $260.8M |
| Stockholders' equity | $6.9M | $9.1M | $14.3M | $14.9M | -$27.3M | -$28.5M | -$33.7M | -$40.0M |
| Total current assets | $229.8M | $229.0M | $238.1M | $229.4M | $210.9M | $212.8M | $209.0M | $195.2M |
| Total current liabilities | $92.1M | $90.5M | $96.1M | $89.7M | $258.6M | $88.6M | $91.5M | $85.5M |
| Cash & equivalents | $20.7M | $26.1M | $28.6M | $43.1M | $16.5M | $19.3M | $25.8M | $25.7M |
| Accounts receivable | $89.6M | $83.7M | $89.6M | $81.0M | $79.9M | $78.7M | $78.9M | $67.0M |
| Inventory | $90.6M | $92.5M | $92.7M | $70.0M | $73.0M | $56.9M | $53.2M | $46.0M |
| Property, plant & equipment | $11.8M | $12.0M | $12.4M | $13.0M | $13.7M | $14.5M | $14.9M | $15.4M |
| Other non-current assets | $5.0M | $5.2M | $5.4M | $5.9M | $6.1M | $6.3M | $6.5M | $6.7M |
| Accounts payable | $11.6M | $9.0M | $9.0M | $12.0M | $12.0M | $12.3M | $11.7M | $10.2M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $5.1M | $4.9M | $4.8M | $4.7M | $747.0K | $682.0K | $615.0K | $241.0K |
| Common stock & paid-in capital | $1.9M | $1.9M | $1.9M | $1.8M | $1.5M | $1.5M | $1.5M | $1.5M |
| Retained earnings | -$1.95B | -$1.95B | -$1.94B | -$1.94B | -$1.92B | -$1.92B | -$1.92B | -$1.92B |
| Accumulated other comprehensive income (loss) | -$6.0K | -$6.0K | $4.0K | $0 | -$1.0K | $1.0K | $13.0K | $40.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.2M | -$1.5M | -$9.2M | $1.3M | -$10.9M | -$8.9M | -$11.8M | $3.4M |
| Investing cash flow | -$3.3M | -$939.0K | -$5.5M | $11.9M | $7.3M | $2.3M | $11.4M | $4.0M |
| Financing cash flow | $82.0K | -$51.0K | $219.0K | $13.4M | $781.0K | $64.0K | $423.0K | $14.0K |
| Free cash flow | -$2.4M | -$1.9M | -$9.2M | $1.3M | -$11.1M | -$9.0M | -$12.4M | $2.9M |
| Capital expenditures | $138.0K | $391.0K | $0 | $0 | $208.0K | $109.0K | $638.0K | $431.0K |
| Depreciation & amortization | $452.0K | $529.0K | $537.0K | $615.0K | $611.0K | $551.0K | $581.0K | $581.0K |
| Share-based compensation | $3.2M | $3.0M | $2.2M | $2.9M | $2.8M | $2.5M | $2.3M | $2.7M |
| Change in accounts receivable | $5.9M | -$5.9M | $8.5M | $1.1M | $1.2M | -$145.0K | $11.8M | -$6.7M |
| Change in inventory | $683.0K | $169.0K | $14.2M | -$2.9M | $16.0M | $3.8M | $7.2M | $3.1M |
| Change in accounts payable | $2.6M | -$24.0K | -$3.0M | -$20.0K | -$296.0K | $624.0K | $1.5M | -$38.0K |
| Purchases of investments | $14.7M | $13.1M | $12.6M | $6.1M | $9.2M | $22.9M | $12.3M | $25.6M |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | — |
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M | -$217.8M |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M |
| EPS (diluted) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
| EPS (basic) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M |
| Stockholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M |
| Total current assets | $238.1M | $209.0M | $188.8M | $205.4M | $254.4M |
| Total current liabilities | $96.1M | $91.5M | $79.7M | $82.4M | $71.1M |
| Cash & equivalents | $28.6M | $25.8M | $28.7M | $15.4M | $90.5M |
| Accounts receivable | $89.6M | $78.9M | $60.1M | $52.0M | $35.5M |
| Inventory | $92.7M | $53.2M | $42.1M | $54.6M | $48.4M |
| Property, plant & equipment | $12.4M | $14.9M | $20.2M | $22.2M | $23.7M |
| Other non-current assets | $5.4M | $6.5M | $8.1M | $15.7M | $17.7M |
| Accounts payable | $9.0M | $11.7M | $3.2M | $3.2M | $3.8M |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — |
| Other non-current liabilities | $4.8M | $615.0K | $241.0K | $241.0K | — |
| Common stock & paid-in capital | $1.9M | $1.5M | $1.5M | $1.2M | $1.0M |
| Retained earnings | -$1.94B | -$1.92B | -$1.91B | -$1.80B | -$1.61B |
| Accumulated other comprehensive income (loss) | $4.0K | $13.0K | $13.0K | -$19.0K | -$6.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M |
| Investing cash flow | $16.0M | $18.7M | $18.0M | -$3.3M | $32.7M |
| Financing cash flow | $14.4M | $940.0K | $54.1M | $75.1M | $156.0M |
| Free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M | -$206.4M |
| Capital expenditures | $317.0K | $1.7M | $1.5M | $1.8M | $3.0M |
| Depreciation & amortization | $2.3M | $2.5M | $2.9M | $2.9M | $3.0M |
| Share-based compensation | $10.3M | $13.0M | $32.9M | $43.0M | $46.9M |
| Change in accounts receivable | $10.7M | $18.7M | $8.1M | $16.6M | -$6.4M |
| Change in inventory | $31.1M | $11.1M | -$12.5M | $6.2M | $6.5M |
| Change in accounts payable | -$2.7M | $8.5M | $15.0K | -$578.0K | $3.3M |
| Purchases of investments | $50.8M | $103.1M | $87.7M | $145.7M | $129.2M |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding HRTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-30 to 2026-10-19
Recent transactions
- Most recent: Duarte Ira (EVP, Chief Financial Officer) — Option exercise of 3,874 shares on 2026-10-19.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Duarte Ira | EVP, Chief Financial Officer | Option exercise | 2026-10-19 | 3,874 |
| Forbes William P | EVP, Chief Development Officer | Option exercise | 2026-10-19 | 3,874 |
| Collard Craig A | Chief Executive Officer | Option exercise | 2026-10-19 | 13,797 |
| Hensley Mark Earl | Chief Operating Officer | Option exercise | 2026-08-06 | 31,250 |
| Christian Waage | Reporting person | Grant / award | 2026-01-30 | 53,960 |
| Kaseta Michael | Reporting person | Grant / award | 2026-01-30 | 53,960 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-19 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 3,874 | — |
| 2026-10-19 | Duarte Ira | EVP, Chief Financial Officer | Tax withholding | 1,102 | $0.36 |
| 2026-10-19 | Forbes William P | EVP, Chief Development Officer | Option exercise | 3,874 | — |
| 2026-10-19 | Forbes William P | EVP, Chief Development Officer | Tax withholding | 1,102 | $0.36 |
| 2026-10-19 | Collard Craig A | Chief Executive Officer | Option exercise | 13,797 | — |
| 2026-10-19 | Collard Craig A | Chief Executive Officer | Tax withholding | 3,360 | $0.36 |
| 2026-08-06 | Hensley Mark Earl | Chief Operating Officer | Option exercise | 31,250 | — |
| 2026-08-06 | Hensley Mark Earl | Chief Operating Officer | Tax withholding | 8,888 | $0.50 |
| 2026-07-31 | Hensley Mark Earl | Chief Operating Officer | Option exercise | 11,769 | — |
| 2026-07-31 | Forbes William P | EVP, Chief Development Officer | Option exercise | 11,694 | — |
| 2026-07-31 | Forbes William P | EVP, Chief Development Officer | Tax withholding | 3,326 | $0.50 |
| 2026-07-31 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 11,694 | — |
| 2026-07-31 | Duarte Ira | EVP, Chief Financial Officer | Tax withholding | 3,326 | $0.50 |
| 2026-07-31 | Collard Craig A | Chief Executive Officer | Option exercise | 34,789 | — |
| 2026-07-30 | Forbes William P | EVP, Chief Development Officer | Option exercise | 11,769 | — |
| 2026-07-30 | Forbes William P | EVP, Chief Development Officer | Tax withholding | 3,348 | $0.50 |
| 2026-07-30 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 13,535 | — |
| 2026-07-30 | Duarte Ira | EVP, Chief Financial Officer | Tax withholding | 3,850 | $0.50 |
| 2026-07-30 | Collard Craig A | Chief Executive Officer | Option exercise | 50,021 | — |
| 2026-07-19 | Collard Craig A | Chief Executive Officer | Option exercise | 13,797 | — |
| 2026-07-19 | Forbes William P | EVP, Chief Development Officer | Option exercise | 3,874 | — |
| 2026-07-19 | Forbes William P | EVP, Chief Development Officer | Tax withholding | 1,101 | $0.47 |
| 2026-07-19 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 3,874 | — |
| 2026-07-19 | Duarte Ira | EVP, Chief Financial Officer | Tax withholding | 1,101 | $0.47 |
| 2026-06-16 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 12,500 | — |
| 2026-06-16 | Duarte Ira | EVP, Chief Financial Officer | Tax withholding | 3,555 | $0.38 |
| 2026-06-06 | Forbes William P | EVP, Chief Development Officer | Option exercise | 12,500 | — |
| 2026-05-06 | Hensley Mark Earl | Chief Operating Officer | Option exercise | 125,000 | — |
| 2026-04-30 | Hensley Mark Earl | Chief Operating Officer | Option exercise | 11,770 | — |
| 2026-04-30 | Forbes William P | EVP, Chief Development Officer | Option exercise | 11,694 | — |
| 2026-04-30 | Forbes William P | EVP, Chief Development Officer | Option exercise | 11,770 | — |
| 2026-04-30 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 11,694 | — |
| 2026-04-30 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 13,535 | — |
| 2026-04-30 | Collard Craig A | Chief Executive Officer | Option exercise | 34,789 | — |
| 2026-04-30 | Collard Craig A | Chief Executive Officer | Option exercise | 50,021 | — |
| 2026-04-19 | Forbes William P | EVP, Chief Development Officer | Option exercise | 3,874 | — |
| 2026-04-19 | Collard Craig A | Chief Executive Officer | Option exercise | 13,797 | — |
| 2026-04-19 | Duarte Ira | EVP, Chief Financial Officer | Option exercise | 3,874 | — |
| 2026-04-03 | Collard Craig A | Chief Executive Officer | Option exercise | 62,500 | — |
| 2026-01-30 | Christian Waage | Reporting person | Grant / award | 53,960 | $0.00 |
| 2026-01-30 | Kaseta Michael | Reporting person | Grant / award | 53,960 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:26 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-21 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-21 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-07-30 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-07-30 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-07-30 | View on SEC.gov → |
Recent news
Headlines about HRTX (Heron Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Form 4 Heron Therapeutics Inc: Craig A. Collard (Director, CEO) For: 19 October
Investing.com Canada · 2026-10-21 -
Heron Therapeutics CEO Craig Collard Converts 13,797 RSUs, Withholds 3,360 Shares for Taxes on Oct 19, 2026
Kalkine Media · 2026-10-21 -
Quarterly stock vesting gives Heron Therapeutics (HRTX) development chief 3,874 shares.
Stock Titan · 2026-10-21 -
Stock awards convert into 13,797 shares for Heron Therapeutics (HRTX) CEO Craig A. Collard.
Stock Titan · 2026-10-21 -
MarketBeat estimates November 3 results for Heron Therapeutics stock
AD HOC NEWS · 2026-10-20 -
Heron Therapeutics, Inc. (HRTX) - What Are Investment Firms Thinking About This Stock?
MarketBeat · 2026-10-20 -
Heron Therapeutics stock sits 77.22 percent below its 52-week high - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
Heron Therapeutics stock at EUR 0.34 as Nasdaq move reaches 4.4 percent - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15
No headlines in this category right now — try “All”.